- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00245128
Imatinib Mesylate in Treating Patients With Myelofibrosis
A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in treating patients with myelofibrosis.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the safety, efficacy, and tolerability of imatinib mesylate in patients with myelofibrosis with myeloid metaplasia.
- Determine the 3-, 6-, and 12-month major and minor erythroid response rates in patients treated with this drug.
Secondary
- Determine reduction in marrow fibrosis in patients treated with this drug.
- Determine decrease in spleen size in patients treated with this drug.
OUTLINE: This is a multicenter, open-label, nonrandomized, pilot study.
Patients receive oral imatinib mesylate once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients who do not experience a minor erythroid response or a 50% reduction in spleen size after 6 months of treatment are removed from the study. Patients experiencing clinical benefit (e.g., ongoing erythroid response) after 1 year of treatment may continue treatment with imatinib mesylate as above at the discretion of the principal investigator.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239-3098
- OHSU Knight Cancer Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Diagnosis of myelofibrosis with myeloid metaplasia (MMM), defined by all of the following:
- Leukoerythroblastic blood picture
- Fibrosis involving > 1/3 sectional area of bone marrow biopsy
- Splenomegaly (unless patient has undergone prior splenectomy)
- Philadelphia chromosome negative
- No myelodysplastic syndrome
- No systemic disorders associated with marrow fibrosis
Red blood cell transfusion dependent, defined by 1 of the following:
- Patient has required ≥ 2 units of red blood cells every 4 weeks within the past 8 weeks
- Hemoglobin ≤ 8 g/dL on ≥ 3 occasions (≥ 2 weeks apart ) over the past 8 weeks
- No evidence of disease transformation to acute myelogenous leukemia, defined as > 20% blasts in bone marrow and/or peripheral blood
PATIENT CHARACTERISTICS:
Performance status
- ECOG 0-3
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count > 1,000/mm^3
- Platelet count > 50,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST or ALT ≤ 2 times ULN (unless due to extramedullary hematopoiesis in the liver)
Renal
- Creatinine ≤ 1.5 times ULN
Cardiovascular
- No New York Heart Association grade III-IV heart disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier method contraception during and for 3 months after completion of study treatment
- No serious, uncontrolled medical condition
- No patients who are considered potentially unreliable or with a history of noncompliance to medical regimens
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 2 weeks since prior interferon alfa
Chemotherapy
- No concurrent chemotherapy except hydroxyurea to control elevated blood counts
Endocrine therapy
- More than 4 weeks since prior corticosteroids, danazol, or other androgens for MMM
Other
- More than 4 weeks since other prior treatment for MMM
- No other concurrent experimental drug therapy for MMM
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Participants With Major and/or Minor Erythroid Responses at 3, 6, and 12 Months of Therapy
Tidsramme: At 3,6, and 12 months of therapy
|
A major response = transfusion independent or a>2.0g/dl rise in hemoglobin without transfusion maintained for at least 8 weeks. Minor response= > 1 to 2.0g/dl incremental rise in hemoglobin maintained for at lease 8 weeks with a decrease in transfusion requirements of at least 50% compared to the mean transfusion requirement during the 8 week pre-study period. |
At 3,6, and 12 months of therapy
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Reduction in Marrow Fibrosis and Decrease in Spleen Size
Tidsramme: After 6 and 12 months of therapy
|
After 6 and 12 months of therapy
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CDR0000445435
- OHSU-541 (Annen identifikator: OHSU IRB)
- OHSU-HEM-01071-L (Annen identifikator: OHSU Knight Cancer Institute)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kroniske myeloproliferative lidelser
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Alcon ResearchFullført
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Sociedad de Lucha Contra el Cáncer del EcuadorFullførtMyeloproliferative lidelser | Myeloproliferativ neoplasma | Myeloproliferativt syndrom | Myeloproliferativ neoplasma, ikke klassifiserbar | Myeloproliferativ sykdom, ikke klassifisertEcuador
-
Mayo ClinicNational Cancer Institute (NCI)AvsluttetMyelodysplastisk/myeloproliferativ neoplasma med ringsideroblaster og trombocytose, ikke spesifisert på annen måte | Myelodysplastisk/myeloproliferativ neoplasma, ikke spesifisert på annen måteForente stater
-
Centre Hospitalier Universitaire de NīmesAktiv, ikke rekrutterendeMyeloproliferativ lidelseFrankrike
-
AUSL Romagna RiminiFullført
-
Astex Pharmaceuticals, Inc.AvsluttetAkutt myeloid leukemi | Myeloproliferativ neoplasma | Myelodysplastisk/myeloproliferativ neoplasmaForente stater, Canada
-
Spectrum Health HospitalsVan Andel Research Institute; Community Foundation for Southeast Michigan...FullførtAML | MDS | Myeloproliferativ lidelseForente stater
-
Sohag UniversityRekrutteringMyeloproliferativ neoplasmaEgypt
Kliniske studier på imatinib mesylate
-
IlDong Pharmaceutical Co LtdFullførtSunnKorea, Republikken
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.FullførtKronisk myeloid leukemi | Gastrointestinal stromal svulstIndia
-
Calgent Biotechnology Co., LtdFullførtResistente eller ildfaste solide svulsterForente stater, Taiwan
-
Merz Pharmaceuticals GmbHAvsluttetSubjektiv tinnitusForente stater, Storbritannia, Polen, Østerrike, Belgia, Brasil, Tsjekkisk Republikk, Frankrike, Tyskland, Mexico, Nederland, Portugal, Sør-Afrika, Spania
-
Pathway Therapeutics, Inc.Fullført
-
Merz Pharmaceuticals GmbHAvsluttetMultippel sklerose | Nystagmus, medfødt | Nystagmus, ErvervetStorbritannia
-
Merz Pharmaceuticals GmbHFullført
-
Dong-A ST Co., Ltd.FullførtKronisk myeloid leukemi | Gastrointestinal stromal svulstKorea, Republikken
-
Oncologia Medica dell'Ospedale FatebenefratelliMario Negri Institute for Pharmacological ResearchFullførtMetastatisk brystkreft | Giftighet | Nevrotoksisitet | Bivirkningshendelse | LegemiddeltoksisitetItalia
-
Merz Pharmaceuticals GmbHFullførtSubjektiv tinnitusForente stater, Østerrike, Tyskland, Brasil, Mexico